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PandemicIn Italy, the COVID-19 vaccination campaign started in December 2020 with the vaccination of healthcare
workers (HCW). To analyse the real-life impact that vaccination is having on this population group, we
measured the association between week of diagnosis and HCW status using log-binomial regression.
By the week 22–28 March, we observed a 74% reduction (PPR 0.26; 95% CI 0.22–0.29) in the proportion
of cases reported as HCW and 81% reduction in the proportion of symptomatic cases reported as HCW,
compared with the week with the lowest proportion of cases among HCWs prior to the vaccination cam-
paign (31 August-7 September). The reduction, both in relative and absolute terms, of COVID-19 cases in
HCWs that started around 30 days after the start of the vaccination campaign suggest that COVID-19 vac-
cines are being effective in preventing infection in this group.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic continues
to affect European countries despite the wide range of interven-
tions implemented since early 2020. One of the most affected
countries has been Italy with 3.4 million people diagnosed with
SARS-CoV-2 infection and over 106,000 associated deaths recorded
up to 28 March 2021 [1]. By March 2021, four vaccines have been
approved by the European Medicines Agency (EMA) and licensed
for use in Italy: BNT162b2 (BioNTech-Pfizer) [2], mRNA-1273
(Moderna) [3], Oxford–AstraZeneca [4] and Ad26.COV2.S (Johnson
& Johnson) [5]. In the European Union (EU), procurement of vacci-
nes for COVID-19 follows a ‘‘centralised approach” and is being
managed by the European Commission [6–8]. By 28 March 2021,
Italy had received 11,197,915 vaccine doses (68.5% BioNTech-
Pfizer, 24.2% Oxford–AstraZeneca and 7.3% Moderna). A two-dose
vaccination strategy is being used, in accordance with the sum-
mary of product characteristics of the specific vaccines, which rec-
ommends an interval of 21 days for the BioNTech-Pfizer vaccine,28 days for Moderna and 10–12 weeks for Oxford-AstraZeneca.
The Italian vaccination campaign started on 27 December 2020
and planned to vaccinate approximately 1.8 million HCWs and
570,287 residents of long-term care facilities (LTCF) in the first
phase, followed by persons over 80 years of age [9]. Although effi-
cacy of COVID-19 vaccines against symptomatic disease has been
proven in clinical trials, there is a need to evaluate the effective-
ness of vaccination campaigns in real-life settings. We describe
the short-term impact of the Italian vaccination campaign on
COVID-19 diagnosis in health care workers (HCW).2. Methods
To describe the impact of vaccination on SARS-CoV-2 infections
among HCWs, we analysed data on vaccine doses retrieved from
the national government’s open data directory [10], and weekly
data on SARS-CoV-2 infections among HCW since 31 August
2020 from the Italian national case-based COVID-19 surveillance
system [11]. This system collects information on all RT-PCR con-
firmed cases of SARS-CoV-2 infection and, since 15 January 2021,
also on cases confirmed through rapid antigen tests (RAT). The
analysis was restricted to cases aged 20–65 years old.
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HCW status using log-binomial regression and adjusting for sex,
age group (20–34, 35–49, and 50–65 years), region of diagnosis,
and regional hospitalisation rate in the previous week. The strength
of the associations is described using prevalence proportion ratios
(PPR) and their 95% confidence intervals (CI). Because HCWs are
tested for SARS-CoV-2 infection more often than non-HCWs, we also
carried the analysis restricting it to symptomatic cases.
HCW status (yes/no) is routinely collected from cases reported
to the surveillance system for COVID-19. However, this informa-
tion was missing in 32.7% out of the 2,149,709 cases included.
We treated these cases as non-HCW, but we conducted a sensitiv-
ity analysis restricted to cases diagnosed in five regions (account-
ing for 50.5% of the total cases) where the proportion of missing
information on HCW status was less than 2% (Supplementary
Material 1). Data on COVID-19 hospital bed occupancy were
retrieved from the Italian Ministry of Health (9).3. Results
From 27 December 2020 to 28 March 2021, 2.98 million vaccine
doses were administered to HCWs, 93.3% of which BioNTech-Pfizer
vaccines, 4.4% Oxford-AstraZeneca and 2.2% Moderna. The cumula-
tive weekly number of doses administered to HCWs increased dur-
ing the first weeks of the vaccination campaign, reaching an
average of 60,585 doses per day in the week from 5 to 11 January
2021 (Table 1).
The total number of cases, as well as the number of cases
reported as HCWs, increased from the first weeks of September
until the first week of November, and decreased after that with aTable 1
Trends in the number of reported COVID-19 cases -total and among healthcare workers (HC
Italy, 1 September 2020 – 28 March 2021.




Total HCW HCW (%) Total HCW
31 Aug  6 Sep 2020 7055 245 3.5 2841 110
7–13 Sep 2020 7198 269 3.7 3097 142
14–20 Sep 2020 7606 310 4.1 3626 155
21–27 Sep 2020 8786 390 4.4 3898 154
28 Sep  4 Oct 2020 12,151 623 5.1 5473 310
5–11 Oct 2020 25,144 1282 5.1 11,673 609
12–18 Oct 2020 49,860 2830 5.7 21,362 1386
19–25 Oct 2020 95,615 5249 5.5 38,234 2413
26 Oct  1 Nov 2020 138,803 7382 5.3 53,796 2950
2–8 Nov 2020 165,633 8374 5.1 65,057 3129
9–15 Nov 2020 162,783 8115 5.0 68,202 3292
16–22 Nov 2020 142,136 7081 5.0 62,296 3221
23–29 Nov 2020 104,917 6116 5.8 45,756 2887
30 Nov  6 Dec 2020 82,836 5941 7.2 39,234 3022
7–13 Dec 2020 69,315 5275 7.6 35,730 2944
14–20 Dec 2020 68,881 4946 7.2 36,416 2718
21–27 Dec 2020 60,286 4247 7.0 32,056 2448
28 Dec 2020–3 Jan 2021 76,165 4460 5.9 41,030 2593
4–10 Jan 2021 78,892 4325 5.5 43,008 2529
11–17 Jan 2021 58,887 3408 5.8 30,597 1954
18–24 Jan 2021 52,894 2908 5.5 27,672 1655
25–31 Jan 2021 51,800 2088 4.0 27,719 1086
1–7 Feb 2021 52,052 1562 3.0 27,859 802
8–14 Feb 2021 52,525 1093 2.1 28,693 574
15–21 Feb 2021 57,241 848 1.5 32,171 460
22–28 Feb 2021 78,564 1088 1.4 43,714 530
1–7 Mar 2021 92,258 1076 1.2 52,001 505
8–14 Mar 20 101,360 1179 1.2 58,173 554
15–21 Mar 2021 96,907 1138 1.2 55,772 559
22 Mar  28 Mar 2021 91,159 1089 1.2 47,169 517
* Hospitalisation rate is presented with one week lag and refers to the previous week a
diagnosis in HCW.
4789similar temporal trend until January 2021. However, the two
curves started to diverge at the end of January, approximately
30 days after the start of the vaccination campaign, with the num-
ber of cases reported as HCWs decreasing and non-HCWs remain-
ing stable until mid-February. At this time point, a new wave of
COVID-19 affected Italy, with cases of SARS-CoV-2 infection
increasing in non-HCWs, but remaining stable in HCWs. The same
pattern was observed when only symptomatic cases were taken
into account (Fig. 1A). Equally, similar trends were also observed
for ICU admission and mortality in HCWs compared with non-
HCWs (Supplementary Material 2).
Similarly, the proportion of cases reported as HCWs followed a
similar trend to the hospitalization rate from COVID-19, with a
time lag of approximately one week. The proportion of cases
reported as HCWs peaked at weeks 7 to 13 December 2020
(7.6%). However, after the start of the vaccination campaign, the
proportion of cases and symptomatic cases reported as HCWs
decreased faster than hospitalization rates (Fig. 1B).
These changes in trends were confirmed with results from the
multivariable analysis. After adjusting, the proportion of HCWs
among cases fluctuated, but no consistent trend was observed
until the week of 18 to 24 January 2021. From this date
onwards, the proportion of cases reported as HCW decreased
consistently and significantly in the following nine weeks
(Fig. 2), with an estimated reduction of 74% (PPR = 0.26, 95%
CI: 0.22–0.29) when considering all cases and of 81% when con-
sidering only symptomatic cases (PPR = 0.19, 95% CI 0.16–0.24)
in the week from the 22 to 28 of March compared to the week
from the 31 August to 7 of September (i.e. the week showing the
lowest proportion of HCWs among diagnosed cases during the
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Fig. 1. Trends in the weekly number of COVID-19 cases (solid line) and symptomatic COVID-19 cases (dashed line) reported as healthcare workers (HCW) and not HCWs (A).
Trend in the proportion of total cases (solid line) and symptomatic cases (dashed line) reported as HCWs with the average daily occupation of hospital beds per week, in Italy
from 1 September to 28th of March (B). Vertical black dotted line: Start of the COVID-19 vaccine campaign (27th of december 2020). Vertical grey dotted line: Start of
administration of second doses of COVID-19 vaccines (17th of January 2021).
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Our findings suggest a reduction in the number of SARS-CoV-2
infection among HCWs in Italy, both in absolute terms and in rel-
ative terms as a proportion of total and symptomatic cases, follow-
ing the start of the COVID-19 vaccination campaign in this
population group.
Our results coincide with those reported in one medical centre
of the US, where they observed a drastic reduction in the percent-
age of positive tests among vaccinated HCWs [12]. In Israel, where
45.3% of the population had received at least one dose of the vac-
cine as of 06 February 2021, a 49% reduction in the number of cases
and a 36% reduction in hospitalizations from COVID-19 has been
reported one month and a half after the start of the vaccination
campaign [13]. Similarly, in the UK, rates of infection and hospital-
izations are falling faster among groups who were offered first the
vaccine [14]. Both countries have found high estimates of vaccine
effectiveness against symptomatic infection seven days after the
second dose: 86% (95 %CI 76–97) in the UK [15]; and 94% (95% CI
87–98) in Israel [16].
Although vaccine effectiveness has been reported as early as
within the first 20 days after the first dose [16], we only saw a4790reduction in the proportion of cases reported as HCWs in the week
of 25–31 January 2021, around 30 days after the start of the vacci-
nation campaign. This is longer than the 21-day period from the
start of the campaign that passed in Israel before the effect of vac-
cination started to be observed. One likely explanation is the differ-
ent speed at which vaccination campaigns were rolled-out in both
countries, with Israel being able to achieve higher vaccine coverage
in a shorter period of time.
Our analysis has several limitations. Firstly, there could be dif-
ferences among regions on which professional categories fall under
the definition of HCW, both in terms of reporting to the epidemio-
logical surveillance and to the national monitoring of the vaccina-
tion campaign. This heterogeneity meant that we did not have a
reliable indicator to compare the incidence of infection of this
group with the rest of the population over time. Secondly, data
openly available on vaccinations does not allow to disaggregate
both by category (e.g. healthcare workers) and by type of dose
(first or second), therefore, from the date when second doses
started to be administered (17 January 2021) we cannot know
how many healthcare workers had each type of dose. Finally, these
results show the impact of the BioNTech-Pfizer alone and we can-
not assess the impact of the other two vaccines approved for use in
Fig. 2. Adjusted prevalence proportion ratio (PPR) of HCWs who tested positive for SARS-CoV-2 infection among all cases (A) and among symptomatic cases (B) by week, with
95% Confidence Intervals (CI); and cumulative number of COVID-19 vaccine doses administered to HCW in Italy (yellow line). 1 September 2020 to 28th of March 2021. The
reference was set to the week of the 03–09 November. PPR was adjusted for sex, age group (i.e., 20–34, 35–49, and 50–65 years), region of diagnosis, and regional
hospitalisation rate in the previous week. Vertical black dotted line: Start of administration of the first doses of the COVID-19 vaccine (27th of december 2020). Vertical grey
dotted line: Start of administration of the second doses of the COVID-19 vaccine (17th of January 2021). (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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administered to HCWs.5. Conclusions
This early analysis shows that the number and the proportion of
cases reported as healthcare workers started to drop significantly
on the week starting on the 25th January 2021, 30 days after the
start of the COVID-19 vaccination campaign. Since then, a consis-
tent reduction in such proportion has been observed, suggesting
that vaccination is being effective in reducing infections in this
group. These results could be used by public health authorities to
promote adhesion to the vaccination campaign in areas with rela-
tive low coverage among healthcare workers.Ethical statement
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